Skip to the page

Data / Drug companies / Breckenridge Pharmaceutical, Inc.

Breckenridge Pharmaceutical, Inc.: 77 products in the FDA NDC directory, labeler code 51991

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Breckenridge Pharmaceutical, Inc. (labeler code 51991) lists 77 products in the FDA National Drug Code Directory, covering 30 finished drugs by generic name. By type: 75 prescription drugs, 2 drugs for further processing. Its main marketing category is generic drugs (ANDA). The newest product started marketing on June 3, 2026.

The request: Watch Breckenridge Pharmaceutical, Inc. (FDA labeler code 51991): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
51991
Products in commercial distribution
77
Packages
151
Finished drugs by generic name
30
Prescription products
75
Over the counter products
0
Controlled substance products
Schedule II 1, Schedule III 2, Schedule IV 2, Schedule V 4
Flagged as original packager
70 of 70 products that carry the flag
Started marketing in the last 12 months
12
Earliest marketing start
July 1, 2004
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)7597.4%
Drugs for further processing22.6%

Products by type

TypeProductsShare
Prescription drugs7597.4%
Drugs for further processing22.6%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet2633.8%
Tablet, film coated1519.5%
Capsule1215.6%
Tablet, extended release56.5%
Capsule, delayed release pellets56.5%
Capsule, extended release45.2%
Tablet, for suspension33.9%
Patch, extended release33.9%
Injection, solution22.6%
Injection, solution, concentrate11.3%
Injection11.3%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Tofacitinib51991-963TabletGeneric drugs (ANDA)June 3, 2026
Tofacitinib51991-329TabletGeneric drugs (ANDA)June 3, 2026
Zolpidem Tartrate51991-982Tablet, extended releaseGeneric drugs (ANDA)May 18, 2026
Zolpidem Tartrate51991-981Tablet, extended releaseGeneric drugs (ANDA)May 18, 2026
Milnacipran Hydrochloride51991-876TabletGeneric drugs (ANDA)March 19, 2026
Milnacipran Hydrochloride51991-037TabletGeneric drugs (ANDA)March 19, 2026
Milnacipran Hydrochloride51991-036TabletGeneric drugs (ANDA)March 19, 2026
Milnacipran Hydrochloride51991-034TabletGeneric drugs (ANDA)March 19, 2026
Pomalidomide51991-346CapsuleGeneric drugs (ANDA)February 28, 2026
Pomalidomide51991-344CapsuleGeneric drugs (ANDA)February 28, 2026
Pomalidomide51991-343CapsuleGeneric drugs (ANDA)February 28, 2026
Pomalidomide51991-342CapsuleGeneric drugs (ANDA)February 28, 2026
Everolimus51991-985TabletGeneric drugs (ANDA)October 30, 2025
Dehydrated Alcohol51991-999Injection, solutionGeneric drugs (ANDA)September 23, 2025
Everolimus51991-992Tablet, for suspensionGeneric drugs (ANDA)January 28, 2025
Everolimus51991-991Tablet, for suspensionGeneric drugs (ANDA)January 28, 2025
Everolimus51991-990Tablet, for suspensionGeneric drugs (ANDA)January 28, 2025
Methadone Hydrochloride51991-002Injection, solutionGeneric drugs (ANDA)December 30, 2024
Terbinafine hydrochloride51991-001TabletDrugs for further processingOctober 1, 2023
Omeprazole51991-995Capsule, delayed release pelletsDrugs for further processingMarch 27, 2023
Lacosamide51991-351Tablet, film coatedGeneric drugs (ANDA)March 18, 2022
Lacosamide51991-350Tablet, film coatedGeneric drugs (ANDA)March 18, 2022
Lacosamide51991-349Tablet, film coatedGeneric drugs (ANDA)March 18, 2022
Lacosamide51991-348Tablet, film coatedGeneric drugs (ANDA)March 18, 2022
Penicillamine51991-974CapsuleGeneric drugs (ANDA)November 12, 2021

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.